In contrast, a single-center retrospective study by Qifei He et al. found that trastuzumab added to perioperative therapy in patients with resectable HER2-positive GC resulted in tumor shrinkage and prolonged OS, but no meaningful improvement in OS was observed when trastuzumab was used as a neoadjuvant therapy (P = 0.126) [49]. The gene discussed is ERBB2; the disease is gastric cancer.